Do analysts prefer TMDIF or NUWE?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Titan Medical 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Nuwellis 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger valuation and earnings, TMDIF or NUWE?

Titan Medical has higher revenue and earnings than Nuwellis. Nuwellis is trading at a lower price-to-earnings ratio than Titan Medical, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Titan Medical $17.63M 0.85 $6.95M $0.05 2.64 Nuwellis $8.27M 0.32 -$17.52M -$132.59 N/A

Is TMDIF or NUWE more profitable?

Titan Medical has a net margin of 0.00% compared to Nuwellis' net margin of -123.38%. Titan Medical's return on equity of -82.31% beat Nuwellis' return on equity. Company Net Margins Return on Equity Return on Assets Titan Medical N/A -82.31% -51.47% Nuwellis -123.38% -623.14% -147.34%

Do analysts prefer IRIX or NUWE?

IRIDEX currently has a consensus target price of $3.00, suggesting a potential upside of 328.14%. Given IRIDEX's stronger consensus rating and higher probable upside, analysts plainly believe IRIDEX is more favorable than Nuwellis. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score IRIDEX 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Nuwellis 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger valuation and earnings, IRIX or NUWE?

IRIDEX has higher revenue and earnings than Nuwellis. IRIDEX is trading at a lower price-to-earnings ratio than Nuwellis, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio IRIDEX $52.67M 0.23 -$4.44M -$0.20 N/A Nuwellis $8.27M 0.32 -$17.52M -$132.59 N/A

Is IRIX or NUWE more profitable?

IRIDEX has a net margin of -6.88% compared to Nuwellis' net margin of -123.38%. IRIDEX's return on equity of 0.00% beat Nuwellis' return on equity. Company Net Margins Return on Equity Return on Assets IRIDEX -6.88% N/A -12.55% Nuwellis -123.38% -623.14% -147.34%

Do analysts rate NUWE or ADGM?

Adagio Medical has a consensus price target of $3.50, suggesting a potential upside of 547.31%. Given Adagio Medical's stronger consensus rating and higher possible upside, analysts clearly believe Adagio Medical is more favorable than Nuwellis. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Nuwellis 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Adagio Medical 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25

Which has higher valuation & earnings, NUWE or ADGM?

Nuwellis has higher revenue and earnings than Adagio Medical. Adagio Medical is trading at a lower price-to-earnings ratio than Nuwellis, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Nuwellis $8.27M 0.32 -$17.52M -$132.59 N/A Adagio Medical $600K 20.01 -$25.08M -$1.48 N/A

Is NUWE or ADGM more profitable?

Adagio Medical has a net margin of 0.00% compared to Nuwellis' net margin of -123.38%. Nuwellis' return on equity of -623.14% beat Adagio Medical's return on equity. Company Net Margins Return on Equity Return on Assets Nuwellis -123.38% -623.14% -147.34% Adagio Medical N/A -661.85% -73.35%

Do analysts rate HSCS or NUWE?

HeartSciences presently has a consensus price target of $8.00, indicating a potential upside of 138.10%. Given HeartSciences' stronger consensus rating and higher probable upside, analysts clearly believe HeartSciences is more favorable than Nuwellis. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score HeartSciences 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Nuwellis 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is HSCS or NUWE more profitable?

HeartSciences has a net margin of 0.00% compared to Nuwellis' net margin of -123.38%. HeartSciences' return on equity of -358.60% beat Nuwellis' return on equity. Company Net Margins Return on Equity Return on Assets HeartSciences N/A -358.60% -144.82% Nuwellis -123.38% -623.14% -147.34%

Does the media prefer HSCS or NUWE?

In the previous week, HeartSciences and HeartSciences both had 1 articles in the media. Nuwellis' average media sentiment score of 0.76 beat HeartSciences' score of 0.00 indicating that Nuwellis is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment HeartSciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Nuwellis 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer MBAI or NUWE?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Check-Cap 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Nuwellis 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is MBAI or NUWE more profitable?

Check-Cap has a net margin of 0.00% compared to Nuwellis' net margin of -123.38%. Check-Cap's return on equity of 0.00% beat Nuwellis' return on equity. Company Net Margins Return on Equity Return on Assets Check-Cap N/A N/A N/A Nuwellis -123.38% -623.14% -147.34%

Does the media favor MBAI or NUWE?

In the previous week, Check-Cap had 2 more articles in the media than Nuwellis. MarketBeat recorded 3 mentions for Check-Cap and 1 mentions for Nuwellis. Nuwellis' average media sentiment score of 0.76 beat Check-Cap's score of 0.00 indicating that Nuwellis is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Check-Cap 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Nuwellis 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Nuwellis (NUWE) Competitors

$0.73 0.00 (-0.58%)

As of 04:00 PM Eastern

Compare

NUWE vs. TMDIF, IRIX, ADGM, HSCS, and MBAI

Should you buy Nuwellis stock or one of its competitors? Nuwellis's main competitors and comparable companies include Titan Medical (TMDIF), IRIDEX (IRIX), Adagio Medical (ADGM), HeartSciences (HSCS), and Check-Cap (MBAI). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare equipment" industry.

How does Nuwellis compare to Titan Medical?

Titan Medical (NASDAQ:TMDIF) and Nuwellis (NASDAQ:NUWE) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, profitability, media sentiment, institutional ownership, risk, dividends, valuation and earnings.

Titan Medical has a net margin of 0.00% compared to Nuwellis' net margin of -123.38%. Titan Medical's return on equity of -82.31% beat Nuwellis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Titan Medical	N/A	-82.31%	-51.47%
Nuwellis	-123.38%	-623.14%	-147.34%

Titan Medical has a beta of 1.26, indicating that its stock price is 26% more volatile than the broader market. Comparatively, Nuwellis has a beta of 0.23, indicating that its stock price is 77% less volatile than the broader market.

0.0% of Titan Medical shares are owned by institutional investors. Comparatively, 3.1% of Nuwellis shares are owned by institutional investors. 0.0% of Titan Medical shares are owned by insiders. Comparatively, 1.6% of Nuwellis shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, Nuwellis had 1 more articles in the media than Titan Medical. MarketBeat recorded 1 mentions for Nuwellis and 0 mentions for Titan Medical. Nuwellis' average media sentiment score of 0.76 beat Titan Medical's score of 0.00 indicating that Nuwellis is being referred to more favorably in the news media.

Company	Overall Sentiment
Titan Medical	Neutral
Nuwellis	Positive

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Titan Medical	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Nuwellis	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Titan Medical has higher revenue and earnings than Nuwellis. Nuwellis is trading at a lower price-to-earnings ratio than Titan Medical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Titan Medical	$17.63M	0.85	$6.95M	$0.05	2.64
Nuwellis	$8.27M	0.32	-$17.52M	-$132.59	N/A

Summary

Titan Medical beats Nuwellis on 8 of the 14 factors compared between the two stocks.

How does Nuwellis compare to IRIDEX?

IRIDEX (NASDAQ:IRIX) and Nuwellis (NASDAQ:NUWE) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, profitability, media sentiment, institutional ownership, risk, dividends, valuation and earnings.

20.1% of IRIDEX shares are owned by institutional investors. Comparatively, 3.1% of Nuwellis shares are owned by institutional investors. 8.6% of IRIDEX shares are owned by insiders. Comparatively, 1.6% of Nuwellis shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, Nuwellis had 1 more articles in the media than IRIDEX. MarketBeat recorded 1 mentions for Nuwellis and 0 mentions for IRIDEX. Nuwellis' average media sentiment score of 0.76 beat IRIDEX's score of 0.00 indicating that Nuwellis is being referred to more favorably in the news media.

Company	Overall Sentiment
IRIDEX	Neutral
Nuwellis	Positive

IRIDEX currently has a consensus target price of $3.00, suggesting a potential upside of 328.14%. Given IRIDEX's stronger consensus rating and higher probable upside, analysts plainly believe IRIDEX is more favorable than Nuwellis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
IRIDEX	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Nuwellis	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

IRIDEX has a beta of 0.62, indicating that its stock price is 38% less volatile than the broader market. Comparatively, Nuwellis has a beta of 0.23, indicating that its stock price is 77% less volatile than the broader market.

IRIDEX has a net margin of -6.88% compared to Nuwellis' net margin of -123.38%. IRIDEX's return on equity of 0.00% beat Nuwellis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
IRIDEX	-6.88%	N/A	-12.55%
Nuwellis	-123.38%	-623.14%	-147.34%

IRIDEX has higher revenue and earnings than Nuwellis. IRIDEX is trading at a lower price-to-earnings ratio than Nuwellis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
IRIDEX	$52.67M	0.23	-$4.44M	-$0.20	N/A
Nuwellis	$8.27M	0.32	-$17.52M	-$132.59	N/A

Summary

IRIDEX beats Nuwellis on 12 of the 16 factors compared between the two stocks.

How does Nuwellis compare to Adagio Medical?

Nuwellis (NASDAQ:NUWE) and Adagio Medical (NASDAQ:ADGM) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, risk, profitability, institutional ownership, media sentiment, earnings and dividends.

Adagio Medical has a net margin of 0.00% compared to Nuwellis' net margin of -123.38%. Nuwellis' return on equity of -623.14% beat Adagio Medical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nuwellis	-123.38%	-623.14%	-147.34%
Adagio Medical	N/A	-661.85%	-73.35%

Adagio Medical has a consensus price target of $3.50, suggesting a potential upside of 547.31%. Given Adagio Medical's stronger consensus rating and higher possible upside, analysts clearly believe Adagio Medical is more favorable than Nuwellis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nuwellis	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Adagio Medical	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

3.1% of Nuwellis shares are owned by institutional investors. Comparatively, 48.1% of Adagio Medical shares are owned by institutional investors. 1.6% of Nuwellis shares are owned by insiders. Comparatively, 7.8% of Adagio Medical shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Nuwellis has higher revenue and earnings than Adagio Medical. Adagio Medical is trading at a lower price-to-earnings ratio than Nuwellis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nuwellis	$8.27M	0.32	-$17.52M	-$132.59	N/A
Adagio Medical	$600K	20.01	-$25.08M	-$1.48	N/A

In the previous week, Nuwellis had 1 more articles in the media than Adagio Medical. MarketBeat recorded 1 mentions for Nuwellis and 0 mentions for Adagio Medical. Nuwellis' average media sentiment score of 0.76 beat Adagio Medical's score of 0.00 indicating that Nuwellis is being referred to more favorably in the media.

Company	Overall Sentiment
Nuwellis	Positive
Adagio Medical	Neutral

Nuwellis has a beta of 0.23, indicating that its share price is 77% less volatile than the broader market. Comparatively, Adagio Medical has a beta of -0.09, indicating that its share price is 109% less volatile than the broader market.

Summary

Adagio Medical beats Nuwellis on 9 of the 16 factors compared between the two stocks.

How does Nuwellis compare to HeartSciences?

HeartSciences (NASDAQ:HSCS) and Nuwellis (NASDAQ:NUWE) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, dividends, profitability, media sentiment, risk, earnings and valuation.

HeartSciences has higher earnings, but lower revenue than Nuwellis. HeartSciences is trading at a lower price-to-earnings ratio than Nuwellis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
HeartSciences	N/A	N/A	-$9.14M	-$3.94	N/A
Nuwellis	$8.27M	0.32	-$17.52M	-$132.59	N/A

17.2% of HeartSciences shares are held by institutional investors. Comparatively, 3.1% of Nuwellis shares are held by institutional investors. 4.9% of HeartSciences shares are held by insiders. Comparatively, 1.6% of Nuwellis shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

HeartSciences presently has a consensus price target of $8.00, indicating a potential upside of 138.10%. Given HeartSciences' stronger consensus rating and higher probable upside, analysts clearly believe HeartSciences is more favorable than Nuwellis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
HeartSciences	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Nuwellis	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, HeartSciences and HeartSciences both had 1 articles in the media. Nuwellis' average media sentiment score of 0.76 beat HeartSciences' score of 0.00 indicating that Nuwellis is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
HeartSciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Nuwellis	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

HeartSciences has a net margin of 0.00% compared to Nuwellis' net margin of -123.38%. HeartSciences' return on equity of -358.60% beat Nuwellis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
HeartSciences	N/A	-358.60%	-144.82%
Nuwellis	-123.38%	-623.14%	-147.34%

HeartSciences has a beta of 1.85, meaning that its stock price is 85% more volatile than the broader market. Comparatively, Nuwellis has a beta of 0.23, meaning that its stock price is 77% less volatile than the broader market.

Summary

HeartSciences beats Nuwellis on 11 of the 14 factors compared between the two stocks.

How does Nuwellis compare to Check-Cap?

Check-Cap (NASDAQ:MBAI) and Nuwellis (NASDAQ:NUWE) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their risk, institutional ownership, profitability, earnings, valuation, media sentiment, analyst recommendations and dividends.

In the previous week, Check-Cap had 2 more articles in the media than Nuwellis. MarketBeat recorded 3 mentions for Check-Cap and 1 mentions for Nuwellis. Nuwellis' average media sentiment score of 0.76 beat Check-Cap's score of 0.00 indicating that Nuwellis is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Check-Cap	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Nuwellis	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Check-Cap has a net margin of 0.00% compared to Nuwellis' net margin of -123.38%. Check-Cap's return on equity of 0.00% beat Nuwellis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Check-Cap	N/A	N/A	N/A
Nuwellis	-123.38%	-623.14%	-147.34%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Check-Cap	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Nuwellis	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Check-Cap has higher earnings, but lower revenue than Nuwellis. Check-Cap is trading at a lower price-to-earnings ratio than Nuwellis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Check-Cap	N/A	N/A	$4.14M	-$14.07	N/A
Nuwellis	$8.27M	0.32	-$17.52M	-$132.59	N/A

1.1% of Check-Cap shares are owned by institutional investors. Comparatively, 3.1% of Nuwellis shares are owned by institutional investors. 0.5% of Check-Cap shares are owned by insiders. Comparatively, 1.6% of Nuwellis shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Check-Cap has a beta of 0.67, suggesting that its stock price is 33% less volatile than the broader market. Comparatively, Nuwellis has a beta of 0.23, suggesting that its stock price is 77% less volatile than the broader market.

Summary

Check-Cap beats Nuwellis on 7 of the 12 factors compared between the two stocks.

Get Nuwellis News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NUWE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

NUWE vs. The Competition

Export

Metric	Nuwellis	Healthcare Equipment & Supplies Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$2.70M	$5.81B	$7.26B	$12.73B
Dividend Yield	N/A	1.76%	2.53%	8.86%
P/E Ratio	-0.01	25.93	273.28	25.38
Price / Sales	0.32	73.29	613.48	92.60
Price / Cash	N/A	33.14	77.82	52.26
Price / Book	-1.31	6.04	12.89	6.14
Net Income	-$17.52M	$150.03M	$3.47B	$349.01M
7 Day Performance	-25.71%	-1.29%	-0.33%	-1.47%
1 Month Performance	-54.37%	3.24%	6.51%	2.47%
1 Year Performance	-99.57%	7.42%	25.19%	15.84%

Nuwellis Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
NUWE Nuwellis	0.7518 of 5 stars	$0.73 -0.6%	N/A	-99.6%	$2.70M	$8.27M	N/A	70
TMDIF Titan Medical	N/A	$0.12 -2.3%	N/A	-63.9%	$13.19M	$17.63M	N/A	50	Gap Down
IRIX IRIDEX	1.6289 of 5 stars	$0.71 -1.2%	$3.00 +324.1%	-46.1%	$12.58M	$52.67M	N/A	120
ADGM Adagio Medical	1.7297 of 5 stars	$0.52 -5.1%	$3.50 +570.5%	-67.7%	$12.22M	$600K	N/A	87
HSCS HeartSciences	2.1624 of 5 stars	$2.99 -0.3%	$8.00 +167.6%	-12.0%	$11.70M	N/A	N/A	10	Upcoming Earnings Short Interest Decrease Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:NUWE) was last updated on 9/3/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Nuwellis (NUWE) Competitors

NUWE vs. TMDIF, IRIX, ADGM, HSCS, and MBAI

How does Nuwellis compare to Titan Medical?

Summary

How does Nuwellis compare to IRIDEX?

Summary

How does Nuwellis compare to Adagio Medical?

Summary

How does Nuwellis compare to HeartSciences?

Summary

How does Nuwellis compare to Check-Cap?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NUWE vs. The Competition

Nuwellis Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Nuwellis (NUWE) Competitors

NUWE vs. TMDIF, IRIX, ADGM, HSCS, and MBAI

How does Nuwellis compare to Titan Medical?

Is TMDIF or NUWE more profitable?

Which has more risk & volatility, TMDIF or NUWE?

Do insiders & institutionals hold more shares of TMDIF or NUWE?

Does the media favor TMDIF or NUWE?

Do analysts prefer TMDIF or NUWE?

Which has stronger valuation and earnings, TMDIF or NUWE?

Summary

How does Nuwellis compare to IRIDEX?

Do insiders & institutionals hold more shares of IRIX or NUWE?

Does the media favor IRIX or NUWE?

Do analysts prefer IRIX or NUWE?

Which has more risk & volatility, IRIX or NUWE?

Is IRIX or NUWE more profitable?

Which has stronger valuation and earnings, IRIX or NUWE?

Summary

How does Nuwellis compare to Adagio Medical?

Is NUWE or ADGM more profitable?

Do analysts rate NUWE or ADGM?

Do institutionals & insiders hold more shares of NUWE or ADGM?

Which has higher valuation & earnings, NUWE or ADGM?

Does the media favor NUWE or ADGM?

Which has more volatility and risk, NUWE or ADGM?

Summary

How does Nuwellis compare to HeartSciences?

Which has better valuation and earnings, HSCS or NUWE?

Do institutionals and insiders believe in HSCS or NUWE?

Do analysts rate HSCS or NUWE?

Does the media prefer HSCS or NUWE?

Is HSCS or NUWE more profitable?

Which has more risk & volatility, HSCS or NUWE?

Summary

How does Nuwellis compare to Check-Cap?

Does the media favor MBAI or NUWE?

Is MBAI or NUWE more profitable?

Do analysts prefer MBAI or NUWE?

Which has preferable valuation and earnings, MBAI or NUWE?

Do insiders and institutionals believe in MBAI or NUWE?

Which has more volatility and risk, MBAI or NUWE?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NUWE vs. The Competition

Nuwellis Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools